Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Raising pre-transfusion HbS levels from 30% to 50% does not increase ischemic stroke recurrence in sickle cell disease: Results from a long-term single-center study

Karina Tozatto-Maio, João Conrado dos Santos, Leonardo Martins, Guilherme Henrique Fonseca, Liliana Suganuma-Otsuka, José Henrique Gomes, Joaquim Gasparini dos Santos, Felipe Nogueira, Afonso Cardoso, Youko Nukui, Vanderson Rocha, Sandra Gualandro

Blood (2025) 146 (Supplement 1): 4738.

https://doi.org/10.1182/blood-2025-4738

Published: 2025

Journal Articles

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study

Jong Wook Lee, Flore Sicre de Fontbrune, Lily Wong Lee Lee, Viviani Pessoa, Sandra Gualandro, Wolfgang Füreder, Vadim Ptushkin, Scott T. Rottinghaus, Lori Volles, Lori Shafner, Rasha Aguzzi, Rajendra Pradhan, Hubert Schrezenmeier, Anita Hill

Blood (2019) 133 (6): 530–539.

https://doi.org/10.1182/blood-2018-09-876136

Published: 2019

Includes: Supplemental data

Journal Articles

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Julie Kanter, MD, Darla Liles, MD, Rodolfo Cancado, MD, PhD, João Friedrisch, MD PhD, Troy H. Guthrie, MD, Jennifer Knight-Madden, MBBS, PhD, Ofelia A. Alvarez, MD, Victor R. Gordeuk, MD, Sandra Gualandro, MD PhD, Marina Pereira Collela, MD PhD, Wally R. Smith, MD, Scott A. Rollins, PhD, Jonathan W. Stocker, PhD, Russell P. Rother, PhD

Blood (2016) 128 (22): 1.

https://doi.org/10.1182/blood.V128.22.1.1

Published: 2016

Journal Articles

Fertility Outcomes after Allogeneic Hematopoietic Stem Cell Transplants Conditioned with Busulfan 4 Mg/Kg and Cyclophosphamide 200 Mg/Kg to Treat Severe Aplastic Anemia

Mariana Nassif Kerbauy, MD, Livia Caroline Barbosa Mariano, MD, Erick Menezes, MD, Evandro Dantas, MD, Jayr Schmidt Sobrinho, MD, Marina M Nascimento, MD, Roberto Silva, MD, Maria Cristina Macedo, MD, Sandra Gualandro, MD PhD, Adriana Seber, MD MS

Blood (2015) 126 (23): 4460.

https://doi.org/10.1182/blood.V126.23.4460.4460

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Raising pre-transfusion HbS levels from 30% to 50% does not increase ischemic stroke recurrence in sickle cell disease: Results from a long-term single-center study

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Fertility Outcomes after Allogeneic Hematopoietic Stem Cell Transplants Conditioned with Busulfan 4 Mg/Kg and Cyclophosphamide 200 Mg/Kg to Treat Severe Aplastic Anemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Raising pre-transfusion HbS levels from 30% to 50% does not increase ischemic stroke recurrence in sickle cell disease: Results from a long-term single-center study

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Fertility Outcomes after Allogeneic Hematopoietic Stem Cell Transplants Conditioned with Busulfan 4 Mg/Kg and Cyclophosphamide 200 Mg/Kg to Treat Severe Aplastic Anemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only